Vijay K. Iyengar - 09 Sep 2026 Form 4 Insider Report for Whitehawk Therapeutics, Inc. (WHWK)

Reporting relationship: Director
Issuer ticker: WHWK
Reported as of: 09 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Sep 2026, 16:04:47 UTC
Prior SEC filing: 17 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ Stephen Rodin, as Attorney-in-Fact

Key filing fact

Vijay K. Iyengar filed Form 4 for Whitehawk Therapeutics, Inc. (WHWK) on 11 Sep 2026.

Key facts

This page summarizes Vijay K. Iyengar's Form 4 filing for Whitehawk Therapeutics, Inc. (WHWK).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 11 Sep 2026, 16:04.

Change

Previous filing in this sequence was filed on 17 Jul 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001670000 Primary reporting owner

Iyengar Vijay K

Relationship: Director
Address: C/O WHITEHAWK THERAPEUTICS, INC., 2 HEADQUARTERS PLAZA, EAST BLDG, 11 FL, MORRISTOWN
Signature: /s/ Stephen Rodin, as Attorney-in-Fact
Signature date: 11 Sep 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

WHWK transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +76,080
Change %
Price: $0.000000^*
Shares after: 76,080
Date: 09 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 76,080
Exercise price: $4.19
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one thirty-sixth (1/36th) of the shares subject to the option shall vest on a monthly basis following the grant date on the same day of the month as the grant date (and if there is no corresponding day, on the last day of the month) such that all shares subject to the option shall be fully vested on the three year anniversary of the grant date. The grant date is September 9, 2026.